Literature DB >> 27771977

Multicenter evaluation of the Luminex® ARIES® HSV 1&2 Assay for the detection of herpes simplex virus types 1 and 2 in cutaneous and mucocutaneous lesion specimens.

Stephen Young1, Barbara Body2, Franklin Moore3, Sherry Dunbar4.   

Abstract

INTRODUCTION: The ARIES® HSV 1&2 Assay is a new FDA cleared real-time PCR test for detection and differentiation of HSV-1 and HSV-2 DNA from cutaneous and mucocutaneous lesions. The test is performed on the ARIES® System, an automated sample to answer real-time PCR instrument that provides a closed system and simple workflow for performing molecular testing. Areas covered: This article reports the clinical performance of the ARIES® HSV 1&2 Assay assessed on 1963 prospectively collected specimens. Assay sensitivities were 91.1-95% (cutaneous) and 97-98.5% (mucocutaneous), and specificities were 88.8-94.2% (cutaneous) and 93.2-95.4% (mucocutaneous), as compared to the ELVIS® HSV test system. Expert commentary: Detection of HSV DNA by PCR is rapid and more sensitive than traditional culture and immunoassay methods and is being widely adopted in many laboratory settings. Sample to answer molecular platforms like ARIES® will enable routine and non-molecular labs to perform sensitive and rapid molecular testing with ease.

Entities:  

Keywords:  Herpes simplex virus; automated test; diagnostic; real-time PCR; sample to answer

Mesh:

Substances:

Year:  2016        PMID: 27771977     DOI: 10.1080/14737159.2016.1251841

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  1 in total

1.  Evaluation of the Luminex ARIES HSV 1&2 Assay and Comparison with the FTD Neuro 9 and In-house Real-Time PCR Assays for Detecting Herpes Simplex Viruses.

Authors:  Chun Kiat Lee; Chean Nee Chai; Sharah Mae Capinpin; Alynn Ang; Sau Yoke Ng; Peak Ling Lee; Christopher Wai Siong Ng; Gabriel Yan; Hong Kai Lee; Lily Lily Chiu; Roland Jureen; Benedict Yan; Tze Ping Loh
Journal:  Ann Lab Med       Date:  2018-09       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.